Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 30 November, 2004

XTL Biopharm Ltd

Appointment of Michael Weiss

XTL Biopharmaceuticals Ltd
30 November 2004

XTLbio announces appointment of Michael S. Weiss, as a non-Executive director

Rehovot, 30 November 2004 - XTL Biopharmaceuticals Ltd. ('XTLbio') (LSE:XTL) is
pleased to announce the appointment of Michael Weiss, as a non-Executive
director with immediate effect.

Michael S. Weiss is currently the Chairman and CEO of Keryx Biopharmaceuticals,
Inc. ('Keryx') (Nasdaq: KERX). Since joining Keryx in December of 2002, Mr.
Weiss successfully completed the restructuring of the company, an acquisition of
a private cancer company, the initiation of a phase II/III clinical program for
a lead drug candidate and two equity capital raising transactions of
approximately $47 million from leading US-based biotechnology funds. Mr. Weiss
was formerly founder, chairman and CEO of ACCESS Oncology, Inc., a private
company focused on in-licensing clinical stage compounds in the oncology area.
Prior to that, Mr. Weiss was Senior Managing Director at Paramount Capital,
Inc., an investment banking firm focused on the biotechnology sector located in
New York, USA. During his tenure from 1993 to 1999, he was responsible for
negotiating and executing private and public investments in biotechnology
companies, including Genta, Inc., a publicly-traded biotechnology company, for
which he managed the turn around in 1997-1999. Mr. Weiss continues to serve on
the Board of Directors of Genta.

Mr. Weiss graduated magna cum laude from State University of New York in 1984
and was awarded a Juris Doctorate degree from Columbia University Law School in

Commenting on the appointment, Dr Geoffrey Vernon, Chairman of XTLbio, said:
'We are pleased to welcome Michael as a non-Executive Director of XTLbio. We are
confident that his experience will further our strategy in the US marketplace.'

Michael Weiss added 'I am very pleased to join XTLbio's board of directors.
XTLbio has interesting products and technologies in an extremely important area
of medical need - the treatment of hepatitis B and hepatitis C'

There are no disclosures required under paragraph 6.F.2. (b)-(g).

Dr. Geoffrey Vernon
Chairman of the Board
+44 7971 475 050

Financial Dynamics
Julia Phillips+44 (0) 20 7831 3113

Notes to Editors

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeXTM product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
XTLbio believes its primary competitive advantage lies in its patented TrimeraTM
technology, which enables the development of fully human monoclonal antibodies
and models of human disease for pre-clinical drug validation. Established in
1993, XTLbio became a public company in 2000 with shares traded on the London
Stock Exchange's market for listed securities under the symbol XTL.

                      This information is provided by RNS
            The company news service from the London Stock Exchange